Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan

TOKYO, November 7, 2012 /PRNewswire/ --

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis Pharma K.K. that it has submitted an application for the registration of QVA149, an investigational fixed dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease (COPD) in Japan.

CEO of Sosei, Shinichi Tamura commented:

"This Japanese application, following on from the recent QVA149 filing in Europe, marks a further important milestone in the approval process for this innovative once-daily combination therapy which has the potential to be a safe and effective, dual-activity bronchodilator for the treatment of COPD patients."

Notes for Editors

About QVA149

QVA149, is an investigational fixed dose combination of two long-acting inhaled bronchodilators - indacaterol maleate and glycopyrronium bromide.

Indacaterol maleate is a long-acting beta2 stimulant that dilates the bronchi by acting on the beta2 receptors in bronchial smooth muscle within 5 minutes of dosing. Glycopyrronium bromide is a long-acting anticholinergic agent that has an antagonistic effect on cholinergic muscarinic receptors related to the contraction of bronchial smooth muscle and thus inhibits bronchoconstriction. Both agents have different mechanisms of action. In clinical studies, both agents demonstrated maintenance bronchodilation over 24 hours administered once daily[1],[2].

Novartis has obtained approval for indacaterol maleate in more than 85 countries around the world (as of October 2012) and it was launched under the brand name Onbrez® Inhalation Capsules 150 g in Japan in September 2011.

Novartis also received approval for glycopyrronium bromide (brand name: Seebri® Inhalation Capsules 50 g) in Japan in September 2012, and this agent was approved in the EU during the same month as Seebri® Breezhaler®. The product has since been launched in Germany and the UK and approvals have also been granted in Canada and Australia.

Glycopyrronium bromide was exclusively licensed to Novartis by Sosei and its co-development partner Vectura in April 2005, for its development and marketing worldwide.

The application for QVA149 was filed to the European Medicines Agency in October 2012 and the US application is planned for 2014.

About COPD

COPD is a chronic, progressive lung disease that is caused by the inhalation of harmful substances such as cigarette smoke over a long period. Its major symptoms include cough, sputum, and dyspnea on exertion. COPD not only greatly decreases the quality of life for patients, but is also a life-threatening disease because its symptoms gradually progress and eventually lead to respiratory failure.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit http://www.sosei.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Reference:

  1. Vogelmeier C, et al. Respir Res. 2010; 11: 135-142.
  2. Verkindre C, et al. Respir Med. 2010; 104: 1482-1489

SOURCE Sosei Group Corporation

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
In Part 1, I looked at what could be behind Facebook’s acquisition of WhatsApp and subsequent purchase of Oculus Rift. How are these seemingly different acquisitions related? There is no question that both Facebook and Google are in a race to build the next-generation computing/communi...
The other day I found myself in a discussion with a prospect regarding the merits of capturing complete stack traces for every transaction that flowed through their production system. You see AppDynamics doesn’t do that; we capture problematic business transactions, and this bloke seem...
In the pharmaceutical industry, the drug development clock is ticking at the rate of warp-speed. As a result, companies are constantly looking for solutions to help them accelerate time to market – and many are realizing that implementing a cloud-based information management system can...
Good morning! Or evening, if you happen to be reading this on the other side of the world. Our topic for today is the internet. What? You already know about the internet? No, no, I don’t mean that internet, the boring old one you use to access YouTube and send Facebook updates, e...
Having an effective BYOD policy is one of the most critical steps to ensuring BYOD success. Learn the basics for securing your company's data and clarifying the process. Employees like the ability to choose. Whether it be choosing the hours they work or whether or not they can teleco...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE